Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls

Barthel, Henryk; Luthardt, Julia; Becker, Georg; Patt, Marianne; Hammerstein, Eva; Hartwig, Kristin; Eggers, Birk; Sattler, Bernhard; Schildan, Andreas; Hesse, Swen; Meyer, Philipp; Wolf, Henrike; Zimmermann, Till; Reischl, Joachim; Rohde, Beate; Gertz, Hermann‐Josef; Reininger, Cornelia; Sabri, Osama

doi:10.1007/s00259-011-1821-1

Cited by 95 publications

(76 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gray matter probability maps as generated by PVELab were binarized using a standard threshold and logically combined with the ROIs. Regional SUV ratios (SUVRs) were calculated using the cerebellar cortex as reference region (11).…”

Section: Pet Data Analysismentioning

confidence: 99%

Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸F-Florbetaben β-Amyloid PET Scans

et al. 2015

Self Cite

View full text Add to dashboard Cite

Neocortical atrophy reduces PET signal intensity, potentially affecting the diagnostic efficacy of β-amyloid (Aβ) brain PET imaging. This study investigated whether partial-volume effect correction (PVEC), adjusting for this atrophy bias, improves the accuracy of 18 F-florbetaben Aβ PET. Methods: We analyzed 18 F-florbetaben PET and MRI data obtained from 3 cohorts. The first was 10 patients with probable Alzheimer disease (AD) and 10 age-matched healthy controls (HCs), the second was 31 subjects who underwent in vivo imaging and postmortem histopathology for Aβ plaques, and the third was 5 subjects who underwent PET and MRI at baseline and 1 y later. The imaging data were coregistered and segmented. PVEC was performed using the voxel-based modified Müller-Gärtner method (PVELab, SPM8). From the PET data, regional and composite SUV ratios (SUVRs) with and without PVEC were obtained. In the MRI data, mesial temporal lobe atrophy was determined by the Scheltens mesial temporal atrophy scale and gray matter volumes by voxel-based morphometry. Results: In cohort 1, PVEC increased the effect on AD-versus-HC discrimination from a Cohen d value of 1.68 to 2.0 for composite SUVRs and from 0.04 to 1.04 for mesial temporal cortex SUVRs. The PVEC-related increase in mesial temporal cortex SUVR correlated with the Scheltens score (r 5 0.84, P , 0.001), and that of composite SUVR correlated with the composite gray matter volume (r 5 −0.75, P , 0.001). In cohort 2, PVEC increased the correlation coefficient between mesial temporal cortex SUVR and histopathology score for Aβ plaque load from 0.28 (P 5 0.09) to 0.37 (P 5 0.03). In cohort 3, PVEC did not affect the composite SUVR dynamics over time for the Aβ-negative subject. This finding was in contrast to the 4 Aβ-positive subjects, in 2 of whom PVEC changed the composite SUVR dynamics. Conclusion: The influence of PVEC on 18 F-florbetaben PET data is associated with the degree of brain atrophy. Thus, PVEC increases the ability of 18 F-florbetaben PET to discriminate between AD patients and HCs, to detect Aβ plaques in the atrophic mesial temporal cortex, and potentially to evaluate changes in brain Aβ load over time. As such, the use of PVEC should be considered for quantitative 18 F-florbetaben PET scans, especially in assessing patients with brain atrophy.

show abstract

Section: Pet Data Analysismentioning

confidence: 99%

Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸F-Florbetaben β-Amyloid PET Scans

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…In this regard, our methodology was similar to that in other studies examining interreader performance in diagnostic imaging with and without an intervention such as computer-aided diagnostic software. Parallel methodology has been used in lung disease, [39][40][41][42][43] breast imaging, 29,[44][45][46] and Alzheimer disease, 26,47 without determining intraobserver variability.…”

Section: 712mentioning

confidence: 99%

Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation

Nayate

Dubroff

Schmitt

et al. 2015

American Journal of Neuroradiology

View full text Add to dashboard Cite

show abstract

“…Ten patients with clinically probable AD and 10 controls were evaluated, with results demonstrating significantly higher SUVRs in the patients with probable AD compared with controls in areas including the frontal, lateral temporal, occipital, parietal, and cingulate cortices (p < 0.01). The tracer was also well tolerated [39].…”

Section: [ 18 F]-av-1 or [F-18]-bay94-9172 Or Florbetabenmentioning

confidence: 92%

Amyloid Imaging: Poised for Integration into Medical Practice

Anand

Sabbagh

2017

Neurotherapeutics

View full text Add to dashboard Cite

Amyloid imaging represents a significant advance as an adjunct in the diagnosis of Alzheimer's disease (AD) because it is the first imaging modality that identifies in vivo changes known to be associated with the pathogenesis. Initially, 11 C-PIB was developed, which was the prototype for many 18 F compounds, including florbetapir, florbetaben, and flutemetamol, among others. Despite the high sensitivity and specificity of amyloid imaging, it is not commonly used in clinical practice, mainly because it is not reimbursed under current Center for Medicare and Medicaid Services guidelines in the USA. To guide the field in who would be most appropriate for the utility of amyloid positron emission tomography, current studies are underway [Imaging Dementia Evidence for Amyloid Scanning (IDEAS) Study] that will inform the field on the utilization of amyloid positron emission tomography in clinical practice. With the advent of monoclonal antibodies that specifically target amyloid antibody, there is an interest, possibly a mandate, to screen potential treatment recipients to ensure that they are suitable for treatment. In this review, we summarize progress in the field to date.

show abstract

Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls

Cited by 95 publications

References 41 publications

Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸F-Florbetaben β-Amyloid PET Scans

Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸F-Florbetaben β-Amyloid PET Scans

Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation

Amyloid Imaging: Poised for Integration into Medical Practice

Contact Info

Product

Resources

About

Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls

Cited by 95 publications

References 41 publications

Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans

Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans

Use of Standardized Uptake Value Ratios Decreases Interreader Variability of [18F] Florbetapir PET Brain Scan Interpretation

Amyloid Imaging: Poised for Integration into Medical Practice

Contact Info

Product

Resources

About

Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸F-Florbetaben β-Amyloid PET Scans

Partial-Volume Effect Correction Improves Quantitative Analysis of ¹⁸F-Florbetaben β-Amyloid PET Scans